AIRDOC-B (02251) stock surged 5.57% in Friday's trading session following the release of its strong interim results for the first half of 2025. The company reported a significant turnaround, swinging from a loss to a profit, and demonstrated growth across its key business segments.

According to the financial report, AIRDOC-B recorded revenue of RMB 83.713 million and a gross profit of RMB 64.103 million for the six months ended June 30, 2025, representing a year-on-year increase of 13.53%. Most notably, the company achieved a profit of RMB 443,000 for the period, compared to a loss of RMB 81.488 million in the same period last year, marking a successful turnaround from loss to profit.

The positive results were driven by strong performance across AIRDOC-B's business lines. The company reported a 20.7% year-on-year increase in active service points for retinal detection AI products, reaching 7,180. Its myopia prevention and control AI products saw a significant 68.1% year-on-year growth in usage, while visual training AI products experienced an 11.6% increase in training sessions. Additionally, AIRDOC-B announced the successful development and launch of a new generation "AIRDOC Stress Resistance Testing Device," expanding its product portfolio and potentially opening new revenue streams. These developments have likely contributed to investor confidence, resulting in the stock's impressive performance.